Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression

Jin,Jing; Li,Zhongxin; Liu,Jianghui; Wu,Yan; Gao,Xing; He,Yutong

doi:10.3892/or.2015.4097

Knockdown of zinc transporter ZIP5 (SLC39A5) expression significantly inhibits human esophageal cancer progression

Authors:
- Jing Jin
- Zhongxin Li
- Jianghui Liu
- Yan Wu
- Xing Gao
- Yutong He
View Affiliations

Affiliations: Cancer Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, General Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: July 1, 2015 https://doi.org/10.3892/or.2015.4097
Pages: 1431-1439

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

ZIP5 is a central player in mammalian zinc metabolism. Studies suggest that ZIP5 is differentially expressed during esophageal tumorigenesis, yet the role of ZIP5 in esophageal cancer cells has not yet been clarified. Immunohistochemistry, western blotting and qRT-PCR techniques were used to detect ZIP5 expression in esophageal squamous cell carcinoma (ESCC) tissues. We established a stable knockdown ZIP5 cell line (KYSE170K) derived from the ESCC cell line KYSE170. We conducted MTT and CCK-8 assays to determine the role of ZIP5 in cell proliferation, Transwell assays to detect migration and invasion, and flow cytometry (FCM) to detect apoptosis and cell cycle percentage using KYSE170K cells. We conducted a gene profiling study to detect the expression of genes related to tumor progression. The results demonstrated that ZIP5 protein and mRNA expression was highest in ESCC, intermediate in para-carcinoma and lowest in normal tissue. ZIP5 knockdown decreased proliferation by 28 and 38%, respectively, according to the MTT and CCK-8 assays. Migration and invasion decreased by 54 and 68%, respectively, according to the Transwell assays. COX2 expression was decreased by 68 and 75% at the mRNA and protein level, respectively, and cyclin D1 mRNA and protein expression was decreased following 62 and 60%, respectively, by knockdown of ZIP5, which upregulated the mRNA and protein expression of E-cadherin by 80 and 60%, respectively. ZIP5 knockdown inhibited the proliferation, migration and invasion of ESCC and suppressed COX2, cyclin D1 and E-cadherin expression, which led to the inhibition of cell progression in ESCC.

View Figures

View References

1	GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. 2012
2	Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in China, 2003–2005: A population-based study. Int J Cancer. 136:1921–1930. 2015. View Article : Google Scholar
3	Zou XN, Taylor PR, Mark SD, Chao A, Wang W, Dawsey SM, Wu YP, Qiao YL and Zheng SF: Seasonal variation of food consumption and selected nutrient intake in Linxian, a high risk area for esophageal cancer in China. Int J Vitam Nutr Res. 72:375–382. 2002. View Article : Google Scholar
4	Makhov P, Golovine K, Uzzo RG, Wuestefeld T, Scoll BJ and Kolenko VM: Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene. 431:39–46. 2009. View Article : Google Scholar :
5	Iguchi K, Otsuka T, Usui S, Sugimura Y and Hirano K: Correlation between ZIP2 messenger RNA expression and zinc level in rat lateral prostate. Biol Trace Elem Res. 112:159–167. 2006. View Article : Google Scholar : PubMed/NCBI
6	Li M, Zhang Y, Liu Z, Bharadwaj U, Wang H, Wang X, Zhang S, Liuzzi JP, Chang SM, Cousins RJ, et al: Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci USA. 104:18636–18641. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wu C, Li D, Jia W, Hu Z, Zhou Y, Yu D, Tong T, Wang M, Lin D, Qiao Y, et al: Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. Nat Genet. 45:632–638. 2013. View Article : Google Scholar : PubMed/NCBI
8	Taylor KM, Vichova P, Jordan N, Hiscox S, Hendley R and Nicholson RI: ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells. Endocrinology. 149:4912–4920. 2008. View Article : Google Scholar : PubMed/NCBI
9	Hogstrand C, Kille P, Nicholson RI and Taylor KM: Zinc transporters and cancer: A potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol Med. 15:101–111. 2009. View Article : Google Scholar : PubMed/NCBI
10	Wang F, Kim BE, Petris MJ and Eide DJ: The mammalian Zip5 protein is a zinc transporter that localizes to the basolateral surface of polarized cells. J Biol Chem. 279:51433–51441. 2004. View Article : Google Scholar : PubMed/NCBI
11	Dufner-Beattie J, Kuo YM, Gitschier J and Andrews GK: The adaptive response to dietary zinc in mice involves the differential cellular localization and zinc regulation of the zinc transporters ZIP4 and ZIP5. J Biol Chem. 279:49082–49090. 2004. View Article : Google Scholar : PubMed/NCBI
12	Kumar A, Chatopadhyay T, Raziuddin M and Ralhan R: Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. Int J Cancer. 120:230–242. 2007. View Article : Google Scholar
13	Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E and La Vecchia C: Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer. 122:1118–1129. 2008. View Article : Google Scholar
14	Gaither LA and Eide DJ: Eukaryotic zinc transporters and their regulation. Biometals. 14:251–270. 2001. View Article : Google Scholar
15	Franklin RB and Costello LC: Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys. 463:211–217. 2007. View Article : Google Scholar : PubMed/NCBI
16	Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM and Kolenko VM: Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: Implications for prostate cancer progression. Carcinogenesis. 27:1980–1990. 2006. View Article : Google Scholar : PubMed/NCBI
17	Fong LY, Sivak A and Newberne PM: Zinc deficiency and methylbenzylnitrosamine-induced esophageal cancer in rats. J Natl Cancer Inst. 61:145–150. 1978.PubMed/NCBI
18	Fong LY, Lau KM, Huebner K and Magee PN: Induction of esophageal tumors in zinc-deficient rats by single low doses of N-nitrosomethylbenzylamine (NMBA): Analysis of cell proliferation, and mutations in H-ras and p53 genes. Carcinogenesis. 18:1477–1484. 1997. View Article : Google Scholar : PubMed/NCBI
19	Fong LY and Magee PN: Dietary zinc deficiency enhances esophageal cell proliferation and N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumor incidence in C57BL/6 mouse. Cancer Lett. 143:63–69. 1999. View Article : Google Scholar : PubMed/NCBI
20	Fong LY, Nguyen VT and Farber JL: Esophageal cancer prevention in zinc-deficient rats: Rapid induction of apoptosis by replenishing zinc. J Natl Cancer Inst. 93:1525–1533. 2001. View Article : Google Scholar : PubMed/NCBI
21	Abnet CC, Lai B, Qiao YL, Vogt S, Luo XM, Taylor PR, Dong ZW, Mark SD and Dawsey SM: Zinc concentration in esophageal biopsy specimens measured by X-ray fluorescence and esophageal cancer risk. J Natl Cancer Inst. 97:301–306. 2005. View Article : Google Scholar : PubMed/NCBI
22	Palmiter RD and Findley SD: Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J. 14:639–649. 1995.PubMed/NCBI
23	Liuzzi JP and Cousins RJ: Mammalian zinc transporters. Annu Rev Nutr. 24:151–172. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kagara N, Tanaka N, Noguchi S and Hirano T: Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. Cancer Sci. 98:692–697. 2007. View Article : Google Scholar : PubMed/NCBI
25	Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK and Chen CS: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst. 94:585–591. 2002. View Article : Google Scholar : PubMed/NCBI
26	Fukazawa EM, Baiocchi G, Soares FA, Kumagai LY, Faloppa CC, Badiglian-Filho L, Coelho FR, Gonçalves WJ, Costa RL and Góes JC: COX-2, EGFR, and ERBB-2 expression in cervical intraepithelial neoplasia and cervical cancer using an automated imaging system. Int J Gynecol Pathol. 33:225–234. 2014. View Article : Google Scholar : PubMed/NCBI
27	Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem. 276:20809–20812. 2001. View Article : Google Scholar : PubMed/NCBI
28	Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I and Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 55:429–434. 2002. View Article : Google Scholar : PubMed/NCBI
29	Smyth GP, Stapleton PP, Barden CB, Mestre JR, Freeman TA, Duff MD, Maddali S, Yan Z and Daly JM: Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. Ann Surg Oncol. 10:455–462. 2003. View Article : Google Scholar : PubMed/NCBI